Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 9/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
| ▸ | PI4KA | P42356 | 5/20 | 0.37 |
| ▸ | PI4K2B | Q8TCG2 | 5/20 | 0.37 |
| ▸ | PI4K2A | Q9BTU6 | 5/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 5/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.37 |
| ▸ | XDH | P47989 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8342338 | 0.89 | ADORA2A (0.49) | ADORA2AADORA1ADORA2BADORA3ERAP1 | |
| Pyrophosphoric Acid SCHEMBL6065977 | 0.84 | ADORA2A (0.44) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL42313 | 0.78 | ADORA2A (0.42) | ADORA2AADORA1ADORA2BADORA3ERAP1 | |
| SCHEMBL17289600 | 0.78 | ADORA2A (0.43) | ADORA2AADORA1ADORA3 | |
| Niacinamide SCHEMBL3281888 | 0.76 | F7 (0.52) | ADORA2AADORA1 | |
| SCHEMBL159639 | 0.75 | ADORA2A (0.40) | ADORA2AADORA1ADORA2BERAP1PI4KA | |
| SCHEMBL953009 | 0.75 | NUDT1 (0.41) | ADORA2AADORA1ADORA2BADORA3ERAP1 | |
| SCHEMBL160304 | 0.75 | ADORA2A (0.40) | ADORA2AADORA1ADORA2BERAP1PI4KA | |
| SCHEMBL842439 | 0.75 | ADORA2A (0.40) | ADORA2AADORA1ERAP1PI4KAPI4K2B | |
| SCHEMBL4581404 | 0.75 | PI4KA (0.41) | ADORA2AADORA1ADORA2BERAP1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2271 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106497-A2 | FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION | SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) | 2026-05-21 | — | — | WO | claimed |
| EP-4619524-A1 | METHODS AND COMPOSITIONS FOR PREVENTING, TREATING, OR REVERSING CARDIAC DIASTOLIC DYSFUNCTION | Genkardia Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250257360-A1 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | UNIV OKLAHOMA (US) | 2025-08-14 | — | — | US | claimed |
| CN-113151261-B | Antisense oligonucleotides as inhibitors of TGF-R signaling | 神经视觉医药有限公司 | 2025-06-17 | — | — | CN | claimed |
| EP-4504945-A2 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | The Board of Regents of the University of Oklahoma (US) | 2025-02-12 | — | — | EP | claimed |
| CN-118931997-A | Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis | 上海飞腾医药科技有限公司 | 2024-11-12 | — | — | CN | claimed |
| US-20240294924-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-09-05 | — | — | US | claimed |
| WO-2024108217-A1 | METHODS AND COMPOSITIONS FOR PREVENTING, TREATING, OR REVERSING CARDIAC DIASTOLIC DYSFUNCTION | GENKARDIA INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2024098061-A2 | OLIGONUCLEOTIDE-BASED THERAPEUTICS TARGETING CYCLIN D2 FOR THE TREATMENT OF HEART FAILURE | GENKARDIA INC. (US) | 2024-05-10 | — | — | WO | claimed |
| CN-117795071-A | Antisense oligonucleotides for preventing renal dysfunction caused by endothelial dysfunction through inhibition of ephrin-B2 | 马克斯·普朗克科学促进学会 | 2024-03-29 | — | — | CN | claimed |
| WO-1994015622-A1 | NUCLEOSIDE DERIVATIVES AND THEIR USE AS EXCITATORY AMINO ACID ANTAGONISTS | CAMBRIDGE NEUROSCIENCE (US) | 1994-07-21 | — | — | WO | claimed |
| EP-0463043-B1 | METHOD FOR STABILIZING THE HYBRIDIZATION OF COMPLEMENTARY POLYNUCLEOTIDE SEQUENCES | OPALE BIOTECHNOLOGY (FR) | 1994-05-18 | — | — | EP | claimed |
| WO-1994003467-A2 | ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1994-02-17 | — | — | WO | claimed |
| EP-0570514-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1993-11-24 | — | — | EP | claimed |
| EP-0540686-A4 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1993-05-26 | — | — | EP | claimed |
| EP-0540686-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES. | US COMMERCE (US) | 1993-05-12 | — | — | EP | claimed |
| WO-1992013869-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1992-08-20 | — | — | WO | claimed |
| US-5118800-A | Oligonucleotides possessing a primary amino group in the terminal nucleotide | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1992-06-02 | — | — | US | claimed |
| WO-1992001700-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1992-02-06 | — | — | WO | claimed |
| US-4266048-A | Synthesis of analogs of 3'-phosphoadenosine 5'-phosphosulfate (PAPS) | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1981-05-05 | — | — | US | claimed |